Výsledky vyhledávání

Akademický článek

Imaging atherosclerosis in rheumatoid arthritis: evidence for increased prevalence, altered phenotype and a link between systemic and localised plaque inflammation

Autor: S. Skeoch, P. L. Hubbard Cristinacce, H. Williams, P. Pemberton, D. Xu, J. Sun, J. James, C. Yuan, T. Hatsukami, P. D. Hockings, M. Y. Alexander, J. C. Waterton, I. N. Bruce

Publikováno v: Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)

Abstract In rheumatoid arthritis (RA), chronic inflammation is thought to drive increased cardiovascular risk through accelerated atherosclerosis. It may also lead to a more high-risk plaque phenotype. We sought to investigate carotid plaque phenotyp

Externí odkaz: https://doaj.org/article/7b4667cb10d54c1c8e1088c2b63bb790

Zobrazit plný text záznamu

Plný text ve formátu HTML

AB0425 WHAT DOES IT MEAN TO BE A DUAL BICLA AND SRI(4) RESPONDER? A POOLED ANALYSIS OF TWO PHASE 3 TRIALS IN PATIENTS WITH SLE

Autor: I. N. Bruce, K. Psachoulia, E. Maho, D. Isenberg, R. van Vollenhoven, R. Furie, E. F. Morand, C. Lindholm, M. Hultquist, R. Tummala

Publikováno v: Annals of the Rheumatic Diseases. 81:1340-1341

BackgroundThe BILAG–based Composite Lupus Assessment (BICLA) and SLE Responder Index ≥4 (SRI[4], based on SLEDAI-2K) are validated composite global measures of clinically meaningful improvement in SLE disease activity. BICLA and SRI(4) responses

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b0c9688a959321f5a2287cbfde5def8d
https://doi.org/10.1136/annrheumdis-2022-eular.900

Zobrazit plný text záznamu

OP0276 PREFERENCES FOR TREATMENTS TO PREVENT RHEUMATOID ARTHRITIS: DISCRETE CHOICE SURVEY OF RHEUMATOID ARTHRITIS PATIENTS’ FIRST-DEGREE RELATIVES IN THE UNITED KINGDOM AND GERMANY

Autor: G. Simons, J. Veldwijk, R. Disantostefano, M. Englbrecht, C. Radawski, L. Valor, J. Humphreys, I. N. Bruce, K. Raza, M. Falahee

Publikováno v: Annals of the Rheumatic Diseases. 81:183-184

BackgroundThere is a growing research focus on the development of interventions to reduce risk of rheumatoid arthritis (RA) in at-risk individuals.(1) A recent survey of the general population asked to assume a 60% risk of RA established that hypothe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6b2284c82324412d5d185bc9025f5bd4
https://doi.org/10.1136/annrheumdis-2022-eular.1579

Zobrazit plný text záznamu

OP0190 COMPREHENSIVE GENETIC AND FUNCTIONAL ANALYSES OF Fc GAMMA RECEPTORS EXPLAIN RESPONSE TO RITUXIMAB THERAPY FOR AUTOIMMUNE RHEUMATIC DISEASES

Publikováno v: Annals of the Rheumatic Diseases. 81:126-127

BackgroundRituximab is widely used to treat rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) but clinical response varies. Efficacy is determined by the efficiency of depletion, which may depend on a variety of Fc gamma receptor (Fcγ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46fc59f5716cb1eb408dada0106defba
https://doi.org/10.1136/annrheumdis-2022-eular.2615

Zobrazit plný text záznamu

POS0757 COVID-19 INFECTION AND RECOVERY AMONGST PATIENTS WITH MODERATE-TO-SEVERE LUPUS DURING THE PANDEMIC: RESULTS FROM THE BILAG-BIOLOGICS REGISTER (BILAG-BR)

Autor: S. Dyball, M. Rodziewicz, E. Sutton, B. Parker, I. N. Bruce

Publikováno v: Annals of the Rheumatic Diseases. 81:665.1-665

BackgroundPatients with systemic lupus erythematosus (SLE) are thought to be at greater risk of severe COVID-19 illness and associated complications due to a combination of inherent aberrant immune responses, immunosuppressive medications and co-morb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::70f5d80c1c9c45d5e2427ea8eac565a4
https://doi.org/10.1136/annrheumdis-2022-eular.2897

Zobrazit plný text záznamu

POS0714 POOLED SAFETY ANALYSIS OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THREE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIALS

Autor: T. Dörner, Y. Tanaka, M. Mosca, I. N. Bruce, M. Cardiel, E. F. Morand, M. A. Petri, M. Silk, C. Dickson, G. Meszaros, M. Issa, L. Zhang, D. J. Wallace

Publikováno v: Annals of the Rheumatic Diseases. 81:639.1-639

BackgroundBaricitinib (BARI), an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheumatoid arthritis and atopic dermatitis, has been evaluated in clinical studies in patients with systemic lupus erythematosus (SLE).Obj

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a67cabee3179d1705faace4a056019e9
https://doi.org/10.1136/annrheumdis-2022-eular.2375

Zobrazit plný text záznamu

POS0591 TREATMENTS TO PREVENT RHEUMATOID ARTHRITIS IN FIRST DEGREE RELATIVES: DEMOGRAPHIC AND PSYCHOLOGICAL PREDICTORS OF RISK TOLERANCES

Autor: G. Simons, E. Janssen, J. Veldwijk, R. Disantostefano, M. Englbrecht, C. Radawski, L. Valor, J. Humphreys, I. N. Bruce, B. Hauber, K. Raza, M. Falahee

Publikováno v: Annals of the Rheumatic Diseases. 81:562.1-562

BackgroundThere is a growing research focus on the development of interventions to reduce risk of rheumatoid arthritis (RA) in at-risk groups.(1) RA patients’ first-degree relatives (FDRs) have an elevated risk of developing RA and are potential ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::15d97d91649e4fa40394f4a73afc09e3
https://doi.org/10.1136/annrheumdis-2022-eular.1611

Zobrazit plný text záznamu

Akademický článek

The Challenges of Dialysis in Systemic Sclerosis: Between the Devil and the Deep Blue Sea?

Autor: N. Brown, A. Summers, M. C. Venning, I. N. Bruce

Publikováno v: Case Reports in Nephrology, Vol 2012 (2012)

We present the case of a patient with systemic sclerosis (SSc) and end stage renal disease (ESRD) who experienced complications of both peritoneal and haemodialysis. We review previously reported outcomes of patients with systemic sclerosis on dialys

Externí odkaz: https://doaj.org/article/63e4c085b21a4bcaac18b32c41fb572a

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání